capecitabine has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 79 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 32 (40.51) | 24.3611 |
| 2020's | 47 (59.49) | 2.80 |
| Authors | Studies |
|---|---|
| Amoroso, D; Baldelli, A; Berardi, R; Butera, A; Cagossi, K; Capici, S; Cavanna, L; Cazzaniga, ME; Ciccarese, M; Cinieri, S; Clivio, L; Cogliati, V; Cretella, E; De Conciliis, E; Di Mauro, P; Febbraro, A; Ferraù, F; Ferzi, A; Fontana, A; Gambaro, AR; Garrone, O; Gebbia, V; Generali, D; Gianni, L; Giovanardi, F; Grassadonia, A; Leonardi, V; Marchetti, P; Montagna, E; Musolino, A; Nicolini, M; Putzu, C; Riccardi, F; Santini, D; Saracchini, S; Sarobba, MG; Sarti, S; Schintu, MG; Scognamiglio, G; Spadaro, P; Taverniti, C; Toniolo, D; Torri, V; Tralongo, P; Turletti, A; Valenza, R; Valerio, MR; Vallini, I; Vici, P | 1 |
| Dizdar, O; Guven, DC; Taban, H | 1 |
| Abu-Shahin, FI; Brown, EN; Liu, L | 1 |
| Adalsteinsson, VA; Asad, S; Collier, KA; Ha, G; Jenison, J; Lin, NU; Mardis, ER; Parsons, HA; Rajkovic, A; Stover, DG; Tallman, D; Tolaney, SM; Winer, EP | 1 |
| Albacker, LA; Badve, S; Bales, CL; Ballinger, TJ; Blaya, M; Cantor, E; Chen, YH; Chitambar, C; Cooper, ME; Daily, K; Falkson, C; Gallagher, C; Graham, R; Gregg, J; Hancock, BA; Helft, P; Isaacs, C; Jiang, G; Kassem, N; Lynce, FC; Mahtani, R; Miller, KD; Nanda, R; O'Neil, B; Paplomata, E; Pavlick, DC; Radovich, M; Schneider, BP; Shen, F; Solzak, JP; Storniolo, AMV; Thompson, MA; Walling, R | 1 |
| Bernard, B; Chang, S; Chun, B; Conlin, AK; Conrad, V; Fields, PA; Kim, I; Koguchi, Y; McArthur, HL; Nikitin, B; Page, DB; Polaske, N; Pucilowska, J; Rajamanickam, V; Redmond, WL; Schmidt, M; Urba, WJ | 1 |
| Brugman, W; de Boo, LW; Hauptmann, M; Joensuu, H; Jóźwiak, K; Kluin, RJC; Kok, M; Lauttia, S; Lindman, H; Linn, SC; Nederlof, PM; Opdam, M; Schouten, PC; van Steenis, C | 1 |
| Fang, H; Liu, M; Qian, S | 1 |
| Huang, X; Ni, J; Xi, X; Yang, F; Yuan, H | 1 |
| Bian, L; Li, N; Wang, X; Wen, J; Xie, X; Ye, F; Yu, P | 1 |
| Barrios, CH; Bear, HD; Joensuu, H; Loibl, S; Martin, M; Miralles, JJ; Möbus, V; Muss, H; Nekljudova, V; Nitz, U; O'Shaughnessy, J; Reimer, T; Seither, F; Steger, GG; Toi, M; Untch, M; van Mackelenbergh, MT | 1 |
| Arıkan, R; Atcı, MM; Ay, S; Ayhan, M; Bayram, E; Dülgar, Ö; Gümüş, M; Öven, BB; Özcan, E; Ozyukseler, DT; Selvi, O; Yasin, Aİ | 1 |
| Fang, Y; Wang, S; Xing, X; Yang, Q; You, S | 1 |
| Alvarez Soto, A; Anampa, JD; Lu, JY | 1 |
| Cai, J; Chen, L; Chen, Y; Ji, Z; Li, Z; Lin, W; Liu, Y; Lu, H; Wu, J; Zheng, J; Zou, J | 1 |
| Boscolo Bielo, L; Burstein, HJ; Curigliano, G; Ferraro, E; Giugliano, F; Trapani, D | 1 |
| Barrios, C; Barroso-Sousa, R; Bonadio, RC; Curigliano, G; Pernas, S; Punie, K; Tarantino, P; Testa, L; Tolaney, SM | 1 |
| Li, JB; Li, M; Li, S; Lin, ZC; Wang, HHX; Wong, MCS | 1 |
| Asleh, K; Ayala, F; Barrios, C; Bines, J; Cejalvo, JM; Gao, D; García-Sáenz, JÁ; Gómez, H; Goytain, A; Guerrero-Zotano, Á; Haba-Rodriguez, J; Herranz, J; Leung, S; Lluch, A; Martin, M; Nielsen, TO; Rojo, F; Ruiz-Borrego, M; Torrecillas, L; Torres, R; Wang, XQ | 1 |
| Andrade, F; Bagnoli, F; Budel, VM; Cavalcante, FP; da Cunha Amaral, RK; Damin, AP; de Lucena Ferreira, NCF; de Lucena, CÊM; de Nigro Corpa, MV; de Oliveira Freitas, AM; de Oliveira, VM; de Souza, ABA; Dos Santos, AMR; Facina, G; Frasson, AL; Freitas, NMA; Freitas-Junior, R; Guará, JP; Machado, RHS; Mansani, FP; Mattar, A; Millen, EC; Novita, G; Passos, M; Pedrini, JL; Reinert, T; Rodrigues, FLB; Ruiz, CA; Soares, LR; Zerwes, FP | 1 |
| Fujita, S; Hattori, A; Hirano, A; Ishibashi, Y; Kamimura, M; Kitano, A; Kodera, A; Shiozawa, S; Yukawa, H | 1 |
| Bozoghlanian, M; Cui, Y; Frankel, PH; Martinez, N; Murga, M; Patel, N; Ruel, C; Schmolze, D; Stewart, D; Tang, A; Tumyan, L; Vora, L; Waisman, J; Yost, SE; Yuan, Y | 1 |
| Anders, CK; Lin, NU; Rader, RK; Sammons, SL | 1 |
| Chai, Y; He, M; Jiang, M; Li, Q; Liu, J; Luo, Y; Ma, F; Wang, J; Wang, Z; Xu, B; Yuan, P | 1 |
| Cakmak Oksuzoglu, OB; Karacin, C; Oner, I; Seyran, E; Tolunay Br, PK; Turkel, A | 1 |
| Bayupurnama, P; Choridah, L; Hutajulu, SH; Iqbal, M; Kurnianda, J; Leo, B; Oktariani, S; Sattwika, PD | 1 |
| Goldstein, LJ; Varshavsky-Yanovsky, AN | 1 |
| Amorim, G; Antón, A; Baena-Cañada, JM; Barnadas, A; Barrios, CH; Bezares, S; Bines, J; Bofill, JS; Calvo, L; Cardemil, B; Cárdenas, J; Carrasco, E; de la Haba, J; Escudero, MJ; Fernández, I; García-Martínez, E; García-Sáenz, JA; Godes, MJ; Gómez, HL; Guerrero-Zotano, Á; Llombart, A; Lluch, A; López-Álvarez, P; Martín, M; Martínez de Dueñas, E; Moncayo, J; Pérez-Michel, L; Ramos, M; Reyes, S; Rodríguez-Lescure, Á; Ruiz-Borrego, M; Sampaio, C; Segalla, J; Seguí, MA; Torrecillas, L; Torres, R; Villar, E; Vinholes, J | 1 |
| Li, Y; Lin, Y; Mao, F; Shen, S; Sun, Q; Zhang, X; Zhou, Y | 1 |
| Asleh, K; Brauer, HA; Chumsri, S; Joensuu, H; Lauttia, S; Lindman, H; Nielsen, TO; Sullivan, A; Thompson, EA | 1 |
| Cristofanilli, M; Flaum, L; Gradishar, W; Helenowski, I; Jain, S; Nelson, V; Rademaker, A; Santa-Maria, CA; Shah, AN; Tsarwhas, D | 1 |
| Bos, MEMM; Bouma, JM; Claessens, AKM; de Graaf, H; Erdkamp, FLG; Honkoop, AH; Lopez-Yurda, M; Rademaker-Lakhai, JM; Tjan-Heijnen, VCG | 1 |
| Cao, Y; Cui, S; Fan, Z; Fu, P; Guo, X; He, P; He, Q; Jiang, G; Jiang, J; Jin, F; Li, J; Li, X; Liu, P; Liu, Y; Ma, B; Mo, M; Pang, D; Qu, X; Rao, N; Ren, G; Shao, Z; Sheng, Y; Sun, Q; Tang, J; Wang, C; Wang, J; Wang, O; Wang, S; Wang, X; Xu, B; Yang, S; Yu, K; Yu, S; Zhang, G; Zhang, H; Zhang, J; Zhuang, Z | 1 |
| Barrios, CH; Lluch, A; Martín, M; Torrecillas, L | 1 |
| Ishiki, H; Satomi, E; Shimomura, A; Usui, Y | 1 |
| Aieta, M; Bordonaro, R; Borsellino, N; Bozza, G; Ciccarese, M; Cilenti, G; Cinieri, S; Colucci, G; Febbraro, A; Fedele, P; Forcignanò, R; Lorusso, V; Maiello, E; Orlando, L; Pisconti, S; Riccardi, F; Rinaldi, A; Romito, S; Saracino, V; Schiavone, P; Surico, G | 1 |
| Baumann, R; Budach, W; Duma, MN; Dunst, J; Feyer, P; Fietkau, R; Haase, W; Harms, W; Hehr, T; Krug, D; Piroth, MD; Sauer, R; Sedlmayer, F; Souchon, R; Strnad, V | 1 |
| Bretes, L; Dias, D; Fortuna, A; Gosalbez, B; Luz, P | 1 |
| Chambers, K; Corral, J; Gaur, S; Konstantinidis, I; McCallum, R; Philipovskiy, A | 1 |
| Bardia, A; Beyerlin, K; Bossuyt, V; Edmonds, C; Ellisen, LW; Fell, GG; Isakoff, SJ; Jimenez, R; Johnson, A; Moy, B; Mulvey, TM; Specht, M; Spring, LM; Zangardi, M | 1 |
| An, X; Bi, XW; Cai, L; Cao, Y; Chen, QJ; Guo, Y; He, ZY; Hong, RX; Hua, X; Huang, H; Huang, JJ; Huang, ZZ; Jiang, KK; Ke, YL; Li, JB; Lin, HX; Lin, Y; Liu, XM; Pang, DM; Peng, RJ; Shi, W; Shi, YX; Song, CG; Su, YH; Tang, J; Wang, SS; Wang, X; Wang, XM; Wang, XY; Xia, W; Xu, F; Xue, C; Yuan, ZY; Zeng, J; Zhang, AQ; Zhang, LH; Zhao, L; Zhong, YY | 1 |
| Burstein, HJ; Parsons, HA | 1 |
| Abdelhamid, MI; Abdelrahman, AE; Alnagar, AA; Elwan, A; Nawar, N | 1 |
| Ahmad, R; Du, F; Huo, X; Li, J; Ren, D; Yuan, X; Zhao, F; Zhao, J | 1 |
| Bi, XW; Hua, X; Yuan, ZY | 1 |
| Akhtar, N; Chakrabarti, D; Kumar, V | 1 |
| Du, F; Yuan, P | 1 |
| Banks, PD; Bulsara, MK; Hoon, SN; Lau, PK; Redfern, AD; White, AM | 1 |
| Arteaga, CL; Block, M; Burnette, BL; DeMichele, AM; Dewani, SJ; Flaum, LE; Garcia, SF; Jani, CR; Makower, DF; Mayer, EL; Mayer, IA; Mescher, C; Miller, KD; Morley, KA; Park, BH; Rodler, ET; Sikov, WM; Smith, KL; Sparano, JA; Symmans, WF; Tawfik, B; Tevaarwerk, AJ; Wagner, LI; Wolff, AC; Zhao, F | 1 |
| Amir, E; Cescon, DW; Ethier, JL; Natori, A | 1 |
| Aogi, K; Im, SA; Im, YH; Iwata, H; Jeong, J; Kim, A; Kim, SB; Kuroi, K; Lee, ES; Lee, SJ; Masuda, N; Ohashi, Y; Ohno, S; Ohtani, S; Park, BW; Park, KH; Sasano, H; Takao, S; Toi, M; Yanagita, Y; Yokota, I | 1 |
| Carey, LA | 1 |
| DeMichele, A; Patel, SA | 1 |
| Denkert, C; Forstbauer, H; Hoffmann, G; Karn, T; Kohls, A; Köhne, CH; Linn, SC; Loibl, S; Marmé, F; Möbus, VJ; Nekljudova, V; Schem, C; Schmatloch, S; Schouten, PC; Solbach, C; Thomssen, C; van Rossum, AGJ; von Minckwitz, G; Weber, KE | 1 |
| Arriaga, L; Babiera, GV; Buchholz, TA; Cohen, EN; Fang, P; Gao, H; Hoffman, K; Le-Petross, H; Middleton, LP; Perkins, GH; Reuben, JM; Smith, BD; Strom, EA; Tereffe, W; Valero, V; Woodward, WA | 1 |
| Lebert, JM; Lester, R; McCarthy, J; Powell, E; Seal, M | 1 |
| Feng, JQ; Jiang, RX; Li, YH; Qian, F; Tong, L; Wang, JG; Wang, XH; Wang, YW; Xiao, L; Xing, SS; Zhang, GJ; Zhao, YL; Zhou, Y | 1 |
| André, F; Cortés, J; Dent, R; Deurloo, R; Easton, V; Gonçalves, A; Kümmel, S; Martín, M; Pollex, E; Schmid, P; Schuetz, F; Swain, SM | 1 |
| Khan, R; Kilkenny, JW; Latif, N; Rana, F; Samiian, L; Tariq, K | 1 |
| Cataruozolo, PE; Cesari, R; Collier, M; Cortés, J; Curigliano, G; Elias, A; Goldhirsch, A; Huang, X; Kern, KA; Khosravan, R; Pivot, X | 1 |
| Fan, Y; Li, J; Liao, Y; Peng, L; Wan, Y | 1 |
| Bartsch, R; Berghoff, AS; Dubsky, P; Fitzal, F; Foedermayr, M; Gnant, M; Preusser, M; Promberger, R; Rudas, M; Sebesta, M; Steger, GG; Weltermann, A; Zach, O; Zielinski, CC | 1 |
| Aftimos, PG; Errihani, H; Mokrim, M; Piccart-Gebhart, M | 1 |
| Higaki, K; Kuroi, K; Masuda, N; Matsunami, N; Miyamoto, T; Mizutani, M; Morimoto, T; Morita, S; Ohno, S; Ohtani, S; Takano, T; Toi, M | 1 |
| De Iuliis, F; Lanza, R; Salerno, G; Scarpa, S; Taglieri, L; Vicinanza, R | 1 |
| Chen, XS; Garfield, DH; Huang, O; Shen, KW; Wu, JY; Yuan, Y | 1 |
| Cox, D; Dranitsaris, G; Faria, C; Gluck, S; Rugo, H | 1 |
| Bos, MM; Boven, E; Braun, JJ; de Groot, SM; Honkoop, AH; Jager, A; Kroep, JR; Lam, SW; Linn, SC; ten Tije, AJ; van den Bosch, J; van Tinteren, H | 1 |
| Galal, S; Shawky, H | 1 |
| Abdelaziz, KK; Alagizy, HA; Hashem, TA; Shehata, MA; Swiha, MM | 1 |
| Cho, JM; Go, SI; Jeon, KN; Kang, JH; Kang, MH; Kim, HG; Kim, MJ; Lee, A; Lee, GW; Lee, JH; Lee, US; Lee, WS | 1 |
| Adamoli, L; Alcalay, M; Bagnardi, V; Bertolini, F; Calleri, A; Criscitiello, C; Curigliano, G; Fumagalli, L; Goldhirsch, A; Locatelli, MA; Rabascio, C; Viale, G | 1 |
| Blomen, V; Brummelkamp, TR; Hoogstraat, M; Janssen, L; Lips, EH; Neefjes, J; Pang, B; Qiao, X; van der Zanden, SY; Wessels, L; Wijdeven, RH | 1 |
| Cai, R; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 2 |
| Cai, R; Du, F; Fan, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Xu, B; Yuan, P; Zhang, P | 1 |
| Kim, HH; Lee, J; Ro, SM; Yang, JH | 1 |
| Ahlgren, J; Auvinen, P; Bono, P; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Junnila, J; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Kosonen, S; Lahdenperä, O; Lindman, H; Nilsson, G; Nyandoto, P; Poikonen-Saksela, P; Tanner, M; Villman, K | 1 |
| Cai, RG; Ding, XY; Fan, Y; Li, Q; Ma, F; Wang, JY; Xu, BH; Yuan, P; Zhang, P | 1 |
17 review(s) available for capecitabine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Capecitabine-induced leukoencephalopathy in a patient with triple-negative breast cancer: A case report and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Fluorouracil; Humans; Leukoencephalopathies; Triple Negative Breast Neoplasms | 2022 |
Additional capecitabine use in early-stage triple negative breast cancer patients receiving standard chemotherapy: a new era? A meta-analysis of randomized controlled trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Disease-Free Survival; Female; Humans; Neoadjuvant Therapy; Progression-Free Survival; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2022 |
Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2022 |
The landscape of systemic therapy for early stage triple-negative breast cancer.
Topics: Capecitabine; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Poly(ADP-ribose) Polymerase Inhibitors; Triple Negative Breast Neoplasms | 2022 |
Addition of Capecitabine to Adjuvant Chemotherapy May be the Most Effective Strategy for Patients With Early-Stage Triple-Negative Breast Cancer: A Network Meta-Analysis of 9 Randomized Controlled Trials.
Topics: Bayes Theorem; Capecitabine; Chemotherapy, Adjuvant; Humans; Network Meta-Analysis; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2022 |
Postneoadjuvant treatment for triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Circulating Tumor DNA; Female; Humans; Neoadjuvant Therapy; Prognosis; Triple Negative Breast Neoplasms | 2022 |
Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Humans; Immune Checkpoint Inhibitors; Neoadjuvant Therapy; Triple Negative Breast Neoplasms | 2022 |
Available Systemic Treatments and Emerging Therapies for Breast Cancer Brain Metastases.
Topics: Brain Neoplasms; Breast Neoplasms; Capecitabine; Female; Humans; In Situ Hybridization, Fluorescence; Prognosis; Receptor, ErbB-2; Trastuzumab; Triple Negative Breast Neoplasms | 2023 |
Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Neoplasm Staging; Prognosis; Retreatment; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Post-neoadjuvant treatment with capecitabine and trastuzumab emtansine in breast cancer patients-sequentially, or better simultaneously?
Topics: Ado-Trastuzumab Emtansine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cardiomyopathies; Clinical Trials as Topic; Combined Modality Therapy; Drug Administration Schedule; Female; Fluorouracil; Humans; Multicenter Studies as Topic; Neoadjuvant Therapy; Prospective Studies; Retrospective Studies; Triple Negative Breast Neoplasms | 2021 |
The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Mastectomy; Neoadjuvant Therapy; Neoplasm Staging; Proportional Hazards Models; Triple Negative Breast Neoplasms | 2021 |
Capecitabine for hormone receptor-positive versus hormone receptor-negative breast cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bias; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoadjuvant Therapy; Quality of Life; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2021 |
Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome; Triple Negative Breast Neoplasms | 2017 |
Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Neoadjuvant Therapy; Neoplasm, Residual; Triple Negative Breast Neoplasms | 2017 |
Advances in the systemic treatment of triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Immunotherapy; Medical Oncology; Mutation; Neoadjuvant Therapy; Paclitaxel; Triple Negative Breast Neoplasms | 2018 |
Breast cancer, DPYD mutations and capecitabine-related ileitis: description of two cases and a review of the literature.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Carcinoma, Ductal; Colitis; Contraindications; Deoxycytidine; Diagnosis, Differential; Diarrhea; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Female; Fluorouracil; Humans; Ileitis; Mutation; Neoplasm Metastasis; Triple Negative Breast Neoplasms | 2014 |
Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carboplatin; Carcinoma, Ductal, Breast; Deoxycytidine; Epothilones; Female; Gemcitabine; Humans; Mastectomy; Multicenter Studies as Topic; Neoadjuvant Therapy; Randomized Controlled Trials as Topic; Remission Induction; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
31 trial(s) available for capecitabine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
BRE12-158: A Postneoadjuvant, Randomized Phase II Trial of Personalized Therapy Versus Treatment of Physician's Choice for Patients With Residual Triple-Negative Breast Cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Capecitabine; Circulating Tumor DNA; Clinical Decision-Making; Disease-Free Survival; Female; High-Throughput Nucleotide Sequencing; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm, Residual; Patient Selection; Precision Medicine; Predictive Value of Tests; Time Factors; Triple Negative Breast Neoplasms | 2022 |
Changes in T-cell subsets and clonal repertoire during chemoimmunotherapy with pembrolizumab and paclitaxel or capecitabine for metastatic triple-negative breast cancer.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Immune Checkpoint Inhibitors; Lymphocyte Depletion; Middle Aged; Neoplasm Metastasis; Paclitaxel; Receptors, Antigen, T-Cell; T-Lymphocyte Subsets; Triple Negative Breast Neoplasms; Young Adult | 2022 |
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Homologous Recombination; Humans; Triple Negative Breast Neoplasms | 2022 |
Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Middle Aged; Paclitaxel; Triple Negative Breast Neoplasms | 2022 |
Triple-Negative PAM50 Non-Basal Breast Cancer Subtype Predicts Benefit from Extended Adjuvant Capecitabine.
Topics: Adjuvants, Immunologic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Endothelial Cells; Female; Humans; Triple Negative Breast Neoplasms | 2023 |
Phase I Trial of Ipatasertib Plus Carboplatin, Carboplatin/Paclitaxel, or Capecitabine and Atezolizumab in Metastatic Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carboplatin; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2023 |
A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2-negative metastatic breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; East Asian People; Female; Humans; Neoplasm Metastasis; Prospective Studies; Receptor, ErbB-2; Treatment Outcome; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2023 |
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Triple Negative Breast Neoplasms; Young Adult | 2020 |
Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Prognosis; Survival Rate; Triple Negative Breast Neoplasms | 2020 |
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Receptor, ErbB-2; Receptors, Progesterone; Salvage Therapy; Survival Rate; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Doxorubicin; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Paclitaxel; Polyethylene Glycols; Progression-Free Survival; Receptor, ErbB-2; Time Factors; Triple Negative Breast Neoplasms | 2020 |
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; China; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Middle Aged; Prospective Studies; Time Factors; Triple Negative Breast Neoplasms | 2020 |
A multicenter phase II trial of nab-paclitaxel and capecitabine in HER-2 negative and triple- negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?
Topics: Albumins; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Female; Humans; Paclitaxel; Triple Negative Breast Neoplasms | 2020 |
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinica
Topics: Adult; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Maintenance Chemotherapy; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Observation; Triple Negative Breast Neoplasms | 2021 |
Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Male; Middle Aged; Neoadjuvant Therapy; Platinum; Triple Negative Breast Neoplasms | 2021 |
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Hand-Foot Syndrome; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Receptor, ErbB-2; Survival Analysis; Triple Negative Breast Neoplasms | 2017 |
BRCA1-like profile is not significantly associated with survival benefit of non-myeloablative intensified chemotherapy in the GAIN randomized controlled trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Humans; Middle Aged; Myeloablative Agonists; Neoplasm Recurrence, Local; Paclitaxel; Triple Negative Breast Neoplasms | 2017 |
A phase 2 study of capecitabine and concomitant radiation in women with advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Preoperative Care; Prospective Studies; Radiotherapy Dosage; Response Evaluation Criteria in Solid Tumors; Triple Negative Breast Neoplasms | 2017 |
IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Capecitabine; Carboplatin; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Deoxycytidine; Female; Gemcitabine; Humans; Mastectomy; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Placebos; Randomized Controlled Trials as Topic; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Efficacy of neoadjuvant cisplatin and oral capecitabine in triple-negative breast cancers: a pilot study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Neoplasm Staging; Pilot Projects; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Disease-Free Survival; Docetaxel; Fatigue; Female; Fluorouracil; Gemcitabine; Hand-Foot Syndrome; Humans; Indoles; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neutropenia; Paclitaxel; Pyrroles; Sunitinib; Survival Rate; Taxoids; Thrombocytopenia; Triple Negative Breast Neoplasms | 2013 |
Acceptable but limited efficacy of capecitabine-based doublets in the first-line treatment of metastatic triple-negative breast cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Odds Ratio; Pilot Projects; Survival Analysis; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2013 |
BRCA-1 methylation and TP53 mutation in triple-negative breast cancer patients without pathological complete response to taxane-based neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; BRCA1 Protein; Capecitabine; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; DNA Methylation; Female; Fluorouracil; Genes, BRCA1; Genes, p53; Germ-Line Mutation; Humans; Male; Methotrexate; Middle Aged; Neoadjuvant Therapy; Paraffin Embedding; Prospective Studies; Taxoids; Triple Negative Breast Neoplasms | 2014 |
A phase II study of metronomic paclitaxel/cyclophosphamide/capecitabine followed by 5-fluorouracil/epirubicin/cyclophosphamide as preoperative chemotherapy for triple-negative or low hormone receptor expressing/HER2-negative primary breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Immunoenzyme Techniques; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triple Negative Breast Neoplasms; Young Adult | 2014 |
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Deoxycytidine; Disease Progression; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy--a single-arm phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Capecitabine; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms | 2014 |
Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer.
Topics: Administration, Metronomic; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Chronotherapy; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Triple Negative Breast Neoplasms | 2015 |
Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Capecitabine; Disease Progression; Endothelial Cells; Female; Gene Expression Profiling; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Pericytes; Survival Analysis; Thoracic Neoplasms; Thoracic Wall; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2015 |
A phase II study of capecitabine plus cisplatin in metastatic triple-negative breast cancer patients pretreated with anthracyclines and taxanes.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Female; Humans; Kaplan-Meier Estimate; Neoplasm Metastasis; Neoplasm Staging; Retreatment; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Epirubicin; Female; Finland; Fluorouracil; Humans; Middle Aged; Receptors, Estrogen; Receptors, Progesterone; Sweden; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms; Young Adult | 2017 |
Docetaxel-cisplatin might be superior to docetaxel-capecitabine in the first-line treatment of metastatic triple-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; ErbB Receptors; Female; Fluorouracil; Humans; Middle Aged; Neoplasm Metastasis; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triple Negative Breast Neoplasms | 2013 |
31 other study(ies) available for capecitabine and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Female; Humans; Receptor, ErbB-2; Retrospective Studies; Triple Negative Breast Neoplasms | 2021 |
Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Neoadjuvant Therapy; Triple Negative Breast Neoplasms | 2022 |
Association of 17q22 Amplicon Via Cell-Free DNA With Platinum Chemotherapy Response in Metastatic Triple-Negative Breast Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell-Free Nucleic Acids; Humans; Platinum; Triple Negative Breast Neoplasms | 2021 |
Adjuvant capecitabine for early triple-negative breast cancer: A meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Randomized Controlled Trials as Topic; Triple Negative Breast Neoplasms | 2022 |
Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy?
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease Progression; Female; Humans; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm, Residual; Prognosis; Triple Negative Breast Neoplasms | 2022 |
[
Topics: Animals; bcl-2-Associated X Protein; Capecitabine; Cyclin D1; Drugs, Chinese Herbal; Heterografts; Humans; Interleukin-6; Mice; Mice, Nude; Proto-Oncogene Proteins c-bcl-2; RNA, Messenger; Signal Transduction; STAT3 Transcription Factor; Triple Negative Breast Neoplasms | 2022 |
A cost-effectiveness analysis of capecitabine maintenance therapy versus routine follow-up for early-stage triple-negative breast cancer patients after standard treatment from a perspective of Chinese society.
Topics: Capecitabine; China; Clinical Trials as Topic; Cost-Benefit Analysis; Follow-Up Studies; Humans; Neoplasm Recurrence, Local; Quality-Adjusted Life Years; Triple Negative Breast Neoplasms | 2022 |
Management of early-stage triple-negative breast cancer: recommendations of a panel of experts from the Brazilian Society of Mastology.
Topics: Brazil; Capecitabine; Humans; Immunotherapy; Neoadjuvant Therapy; Triple Negative Breast Neoplasms | 2022 |
[Adjuvant Capecitabine for Residual Disease after Standard Neoadjuvant Chemotherapy Among Patients with Triple-Negative Breast Cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Triple Negative Breast Neoplasms | 2022 |
Adjuvant Capecitabine after Neoadjuvant Chemotherapy in Triple Negative Breast Cancer with Lymph Node Metastasis.
Topics: Adjuvants, Immunologic; Capecitabine; Humans; Lymphadenopathy; Lymphatic Metastasis; Neoadjuvant Therapy; Triple Negative Breast Neoplasms | 2023 |
Impressive Response to Capecitabine in a Patient with Obstructive Jaundice due to Metastatic Triple-Negative Breast Cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Capecitabine; Female; Humans; Jaundice, Obstructive; Middle Aged; Neoplasm Grading; Neoplasm Staging; Radiography; Tomography, X-Ray Computed; Treatment Outcome; Triple Negative Breast Neoplasms | 2019 |
Role of Capecitabine in Early Breast Cancer.
Topics: Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Fluorouracil; Humans; Triple Negative Breast Neoplasms | 2020 |
Reply to Y. Usui et al.
Topics: Capecitabine; Chemotherapy, Adjuvant; Humans; Reference Standards; Triple Negative Breast Neoplasms | 2020 |
Suggestions Regarding the GEICAM/2003-11_CIBOMA/2004-01 Trial: Future Treatment Options for Early Triple-Negative Breast Cancer.
Topics: Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Humans; Receptor, ErbB-2; Reference Standards; Triple Negative Breast Neoplasms | 2020 |
How shall we treat locally advanced triple negative breast cancer?
Topics: Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Humans; Immunotherapy; Neoadjuvant Therapy; Platinum Compounds; Triple Negative Breast Neoplasms | 2019 |
Remarkable response to combined immunochemotherapy in patients with metastatic triple-negative breast cancer.
Topics: Adult; Aged; Albumins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Female; Humans; Immunotherapy; Middle Aged; Paclitaxel; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Fluorouracil; Humans; Neoadjuvant Therapy; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms | 2021 |
Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations.
Topics: Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Maintenance; Triple Negative Breast Neoplasms | 2021 |
Clinicopathological Features and Treatment Challenges in Triple Negative Breast Cancer Patients: A Retrospective Cohort Study.
Topics: Administration, Metronomic; Adult; Aged; Androgen Antagonists; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Female; Humans; Middle Aged; Nitriles; Retrospective Studies; Risk Factors; Time Factors; Tosyl Compounds; Triple Negative Breast Neoplasms; Young Adult | 2021 |
Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer-Reply.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Triple Negative Breast Neoplasms | 2021 |
Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Triple Negative Breast Neoplasms | 2021 |
Effect of Adjuvant Metronomic Capecitabine on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Triple Negative Breast Neoplasms | 2021 |
De-escalating and escalating systemic therapy in triple negative breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Capecitabine; Chemotherapy, Adjuvant; Female; Humans; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm, Residual; Platinum Compounds; Taxoids; Triple Negative Breast Neoplasms; Tumor Burden | 2017 |
Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Capecitabine; Disease-Free Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Follow-Up Studies; Hemorrhage; Humans; Middle Aged; Pyridines; Retreatment; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms | 2018 |
Elderly woman with triple-negative metastatic breast cancer successfully treated with metronomic capecitabine.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Bone Neoplasms; Brain Neoplasms; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Quality of Life; Tomography, X-Ray Computed; Triple Negative Breast Neoplasms | 2014 |
Comparative effectiveness analysis of monotherapy with cytotoxic agents in triple-negative metastatic breast cancer in a community setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Cytotoxins; Deoxycytidine; Disease-Free Survival; Female; Furans; Gemcitabine; Humans; Ketones; Middle Aged; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2015 |
Irinotecan and capecitabine combination chemotherapy in a patient with triple-negative breast cancer relapsed after adjuvant chemotherapy with anthracycline and taxane.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Camptothecin; Capecitabine; Chemoradiotherapy; Chemotherapy, Adjuvant; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Irinotecan; Magnetic Resonance Imaging; Middle Aged; Pelvic Bones; Positron-Emission Tomography; Recurrence; Taxoids; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Genome-Wide Identification and Characterization of Novel Factors Conferring Resistance to Topoisomerase II Poisons in Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Capecitabine; Carcinoma; Chromosomal Proteins, Non-Histone; CRISPR-Cas Systems; Cyclophosphamide; DNA Helicases; DNA-Binding Proteins; Docetaxel; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Gene Expression Profiling; Genome-Wide Association Study; Humans; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Neoplasm Proteins; Nuclear Proteins; RNA Interference; RNA, Small Interfering; Sarcoma; SMARCB1 Protein; Taxoids; Topoisomerase II Inhibitors; Topotecan; Transcription Factors; Triple Negative Breast Neoplasms | 2015 |
[Efficacy and toxicity of vinorelbine (NVB)-based regimens in patients with metastatic triple negative breast cancer (mTNBC) pretreated with anthracyclines and taxanes].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Capecitabine; Cisplatin; Disease-Free Survival; Humans; Neutropenia; Retrospective Studies; Taxoids; Triple Negative Breast Neoplasms; Vinblastine; Vinorelbine | 2015 |
[Efficacy and safety of cisplatin plus capecitabine for patients with metastatic triple negative breast cancer progressing after anthracycline and taxane treatment].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Capecitabine; Cisplatin; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Leukopenia; Neutropenia; Prospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2015 |
Capecitabine and cisplatin (XP) combination systemic chemotherapy in heavily pre-treated HER2 negative metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Capecitabine; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Female; Gene Expression; Humans; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neutropenia; Receptor, ErbB-2; Retrospective Studies; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2017 |